Edwards Lifesciences Renews $750 Million Credit Line And Pushes Maturity To 2031
The heart-device maker had drawn nothing under the renewed facility and can seek another $375 million with lenders' agreement.
Edwards Lifesciences, which makes heart valves and related structural-heart devices, renewed its $750 million credit line Thursday and extended its maturity to 2031. The company said in its SEC filing that the terms improved on its previous agreement; the renewed facility was entirely undrawn.
Unused Credit, More Capacity Possible
Bank of America administers the unsecured facility, which lets Edwards and participating subsidiaries borrow, repay and borrow again. Edwards expects to put any loans toward general corporate needs.
The company can request another $375 million of borrowing capacity, but lenders must agree and the contract's requirements must be met. That expansion is an option under the agreement.
The renewal replaces the financing arrangement Edwards and subsidiary borrowers established on July 15, 2022. That predecessor agreement likewise allowed them to take loans over its life.
A Fee Even Without Borrowing
Benchmark-linked loans start at a 0.910% interest margin. Edwards also pays an annual facility fee of 0.09% on commitments, including capacity it leaves unused.
Dollar loans carry variable interest tied to the Secured Overnight Financing Rate or a base rate, at Edwards' election. The applicable margin depends on its debt ratings or leverage ratio, a measure of debt relative to earnings.
The agreement includes $525 million in multicurrency commitments within the total facility. Available borrowing currencies include U.S. dollars, euros, sterling, Swiss francs, Japanese yen and Singapore dollars.
Edwards must stay within a maximum leverage ratio and comply with restrictions on debt, asset pledges, mergers and significant asset sales. A default could allow lenders to demand repayment and terminate the facility.
Heart Valves Across Global Markets
Edwards sells in approximately 100 countries. Its 2025 net sales were split 58% from the United States and 42% from elsewhere, where it uses direct sales teams and independent distributors.
Catheter-delivered aortic valve replacement products accounted for 74% of 2025 net sales. Mitral and tricuspid catheter therapies contributed 9%, and surgical tissue heart valves supplied 17%.
Its customers include hospitals, physicians and other clinical staff, hospital purchasing groups and health ministries. No customer represented 10% or more of 2025 net sales.
The renewed credit line matures on November 19, 2031.
Sources
- 8-K Filing — Edwards Lifesciences Corp (EW) — SEC EDGAR
- Exhibit exhibit-creditagreementx.htm — Edwards Lifesciences Corp 8-K exhibit — SEC EDGAR